Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Open-market buy 10% owner bought 140,786 shares at an average $10.80 ($1,520,909)
  7. 4 Open-market buy 10% owner bought 190,079 shares at an average $9.33 ($1,773,653)
  8. 4/A Open-market buy 10% owner bought 202,623 shares at an average $8.28 ($1,677,083)
  9. 4 Open-market buy 10% owner bought 202,623 shares at an average $8.28 ($1,677,083)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Other disposition Director disposed of 1,543,989 shares (other)
  12. 4 Open-market buy 10% owner bought 2,480,032 shares at $15.50 ($38,440,496)
  13. 4 Open-market buy VP Global Regulatory & Quality bought 3,575 shares at $17.81 ($63,671)
  14. 4 Open-market sale VP Technical Operations sold 35,887 shares at $18.67 ($670,010)
  15. 4 Open-market sale CFO, Vice President Finance sold 29,079 shares at $18.67 ($542,905)
  16. 4 Open-market buy VP Global Regulatory & Quality bought 1,600 shares at $24.36 ($38,976)
  17. 4 Open-market sale 10% owner sold 259,927 shares at an average $26.47 ($6,880,295)
  18. 4 Open-market sale 10% owner sold 1,514,821 shares at an average $22.41 ($33,944,876)
  19. 3/A Insider 3/A
  20. 3 Insider Initial Statement of Ownership

Page 12 of 15 · 287 filings